🇺🇸 FDA
Pipeline program

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

J5M-OX-JOXA

Phase 1 other active

Quick answer

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors for Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).

Program details

Company
Eli Lilly Co.
Indication
Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor
Phase
Phase 1
Modality
other
Status
active

Clinical trials